Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Two struggling biotechnology companies are being acquired by stronger firms. MediciNova has entered a deal to acquire Avigen for about $37 million. Both firms have been developing neurological drugs based on ibudilast and its analogs. In May, Avigen dismissed the majority of its employees and embarked on a plan to dissolve itself. Meanwhile, Ligand Pharmaceuticals will acquire Neurogen under a deal in which Neurogen shareholders receive $11 million in Ligand stock plus cash payments if certain milestones are hit. In May, Neurogen laid off half its staff and began exploring a sale of assets or other strategic options.
This article has been sent to the following recipient: